Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Posaconazole

Nature Reviews Drug Discovery volume 6, pages 183–184 (2007)Cite this article

Abstract

Posaconazole (Noxafil; Schering–Plough), a triazole antifungal drug, was approved by the US FDA in September 2006 for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections owing to being severely immunocompromised.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Posaconazole.

References

  1. Kauffman, C. A. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 9, 483–488 (2006).

    Article  CAS  Google Scholar 

  2. Torres, H. A. et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5, 775–785 (2005).

    Article  CAS  Google Scholar 

  3. Odds, F. C. et al. Antifungal agents: mechanisms of action. Trends Microbiol. 11, 272–279 (2003).

    Article  CAS  Google Scholar 

  4. Bennett, F. et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg. Med. Chem. Lett. 16, 86–90 (2006).

    Article  Google Scholar 

  5. Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335–347 (2007).

    Article  CAS  Google Scholar 

  6. Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348–359 (2007).

    Article  CAS  Google Scholar 

  7. FDA labelling information [online], < http://www.fda.gov/cder/foi/label/2006/022003lbl.pdf > (2006).

  8. Kauffman, C. A. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis. 39, 588–590 (2004).

    Article  Google Scholar 

  9. Greenberg, R. N. et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126–133 (2006).

    Article  CAS  Google Scholar 

  10. Van Burik, J. H. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42, e61–e65 (2006).

    Article  CAS  Google Scholar 

  11. Walsh, T. J. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44, 2–12 (2007).

    Article  CAS  Google Scholar 

  12. Raad, I. I. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42, 1398–1403 (2006).

    Article  CAS  Google Scholar 

  13. Anstead, G. M. et al. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis. 40, 1770–1776 (2005).

    Article  CAS  Google Scholar 

  14. Johnson, L. B. & Kauffman, C. A. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630–637 (2003).

    Article  CAS  Google Scholar 

  15. Sansone-Parsons, A. et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50, 1881–1883 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carol A. Kauffman and Anurag N. Malani are at the University of Michigan, Veterans Affairs Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, Michigan 48105, USA. ckauff@umich.edu malanian@umich.edu,

    Carol A. Kauffman & Anurag N. Malani

  2. Chris Easley is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. ceasley@uk.imshealth.com,

    Chris Easley

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Carol A. Kauffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anurag N. Malani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Easley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kauffman, C., Malani, A., Easley, C. et al. Posaconazole. Nat Rev Drug Discov 6, 183–184 (2007). https://doi.org/10.1038/nrd2270

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2270

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing